Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection

被引：0
作者：
Katherine A. Lyseng-Williamson
Lesley J. Scott
机构：
[1] Adis,
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Efavirenz; Tenofovir Disoproxil Fumarate; Virological Failure; Emtricitabine; Etravirine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Eviplera™ [EU]; Complera™ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient population, rilpivirine plus emtricitabine/tenofovir disoproxil fumarate was noninferior to efavirenz plus emtricitabine/tenofovir disoproxil fumarate in terms of reducing viral HIV-1 RNA level to <50 copies/mL and was generally better tolerated than efavirenz plus emtricitabine/tenofovir disoproxil fumarate.
引用
收藏
页码：715 / 722
页数：7
相关论文
共 32 条
[1]  
Camacho R.(2011)Antiretroviral therapy in treatment-naive patients with HIV infection Curr Opin HIV AIDS 6 S3-11
[2]  
Teófilo E.(2011)Recent advances in antiretroviral treatment and prevention in HIV-infected patients Curr Opin HIV AIDS 6 S21-30
[3]  
Maltêz F.(2010)Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents Ann Pharmacother 44 157-65
[4]  
Dorona M.(2009)HIV-1 resistance to first-and second-generation non-nucleoside reverse transcriptase inhibitors AIDS Rev 11 165-73
[5]  
Branco T.(2012)Rilpivirine Drugs 72 525-41
[6]  
Adams J.(2003)Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective Nat Rev Drug Discov 2 812-22
[7]  
Patel N.(2009)Etravirine and rilpivirine: non-nucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents Pharmacotherapy 29 281-94
[8]  
Mankaryous N.(2010)TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1 Antimicrob Agents Chemother 54 718-27
[9]  
Ghosn J.(2011)Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial Lancet 378 238-46
[10]  
Chaix M.L.(2011)Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Lancet 378 229-37
1234